SRNE - Sorrento Therapeutics: Wide Oncology Pipeline And Watch Out For COVID Updates

• First, a striking point about Sorrento Therapeutics is that despite its $1.93 billion market cap, it possesses a wide pipeline, similar to the biggest biopharmaceuticals.
• Second, it is also generating revenues mainly from a prescription drug and has been able to get EUA approval for COVISTIX testing kits, a space that should be closely watched by investors before investing.
• On the other hand, it is spending colossal amounts on clinical development, has debts with limited cash at hand.
• Not possessing any first-mover advantage, its anti-COVID therapies still matter given the prevalence of highly infectious variants and the time-limited protection conferred by vaccines.
• Analyzing the pipeline, there are assets which the company could monetize in the worst-case scenario that finances cannot be raised to fund promising oncology operations or service debt.

For further details see: